Skip to main content

Table 1 Clinical and pathological data of morphologically normal prostatic tissue and prostate cancer patients submitted to a prostate biopsy (cohort #1) included in this study

From: Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients

  (Cohort #1)
Clinicopathological data MNPT PCa (biopsies)
Patients, n 15 74
Median age, years (range) 64 (45–80) 69 (51–85)
Median PSA (ng/mL) (range) n.a. 18.22 (4.52–542.00)
Clinical stage, n (%)
 II n.a. 48 (64.86)
 III n.a. 12 (16.22)
 IV n.a. 14 (18.92)
Prognostic grade group, n (%)
 1 n.a. 30 (40.54)
 2 n.a. 17 (22.97)
 3 n.a. 16 (21.62)
 4 n.a. 7 (9.46)
 5 n.a. 4 (5.41)
CAPRA score, n (%)
 Low risk (0–2) n.a. 7 (9.46)
 Intermediate risk (3–5) n.a. 26 (35.14)
 High risk (6–10) n.a. 41 (55.41)
D’Amico risk classification, n (%)
 Low risk   7 (9.46)
 Intermediate risk   23 (31.08)
 High risk   44 (59.46)
Treatment
 Radical prostatectomy/radiotherapy   39 (52.70)
 Hormonotherapy   35 (47.30)
Follow-up
 Median (months, IQR) n.a. 104.04 (67.03–145.48)
 Patients without remission, n (%) n.a. 3 (4.05)
 Biochemical recurrence, n (%) n.a. 13 (33.33)
 Progression of disease, n (%) n.a 16 (45.71)
 Death due to PCa, n (%) n.a. 13 (17.57)
  1. MNTP morphologically normal prostate tissue, PCa prostate cancer, IQR interquartile range, n.a not applicable